Analysis of the Use of Imiglucerase and It��s Revelation on the Establishment of Rare Disease Medical Security System
KONG Jian,MEI Dan,ZHANG Bo*
Department of Pharmacy, Peking Union Medical College Hospital, Center for the Research of Translational Medicine, Chinese Academy of Medical Science-Peking Union Medical College, Beijing 100730, China
Abstract��OBJECTIVE To explore the burden for treating patients with Gaucher disease and provide a reference for the establishment of rare diseases medical securitysystem in China. METHODS The basic information of the patients enrolled in this study and the prescriptions of the imiglucerase from 2009-2015 in our hospital were analyzed. The total number of patients diagnosed with Gaucher disease, the total cost of Imiglucerase and the average Imiglucerase cost per patient per year were focused by us. RESULTS A total of 35 patients received imiglucerase from our hospital between 2009 and 2015.The enrolled patients increased from 25 to 35 in the past seven years.Annual growth rate is about 5.7% (1.4 patient per year).The total cost for imiglucerase is 130.065 million RMB. The average annual drug cost per patient is 918.6 thousands RMB from 2010 to 2015. CONCLUSION In the past seven years, the number of patients with Gaucher disease in our hospital increased slightly. Due to the high drug costs of Gaucher disease, it is hardly for patients to pay for the drug themselves, and it is suggested to establish a multiple payment mechanism for rare disease.
��,÷��,�Ų�. ��Ժ������ø��ҩ��������Ժ�������ҩ������ϵ����ʾ[J]. �й�ҩѧ��־, 2016, 51(15): 1345-1348.
KONG Jian,MEI Dan,ZHANG Bo. Analysis of the Use of Imiglucerase and It��s Revelation on the Establishment of Rare Disease Medical Security System. Chinese Pharmaceutical Journal, 2016, 51(15): 1345-1348.
LING H, LIU N. Rare disease need to be concerned����rare diseases China charity federation rescue plan started in Beijing[J]. China Med Herald(�й�ҽҩ����), 2009, 6(24):4.
[2]
Lysosomal storage GSDS medical group. Chinese gaucher disease diagnosis and expert consensuseditorial committee. Chinese gaucher disease diagnosis and expert consensus[J]. Natl Mde J China(�л�ҽѧ��־), 2011, 91(10): 665-668.
[3]
LI J, ZHENG J J, ZHU Z H. Gaucher disease and its enzyme replacement therapy drug����imiglucerase[J]. Chin Pharm J(�й�ҩѧ��־),2010, 45(3):237-238.
[4]
GENZYME. PROPOSED TEXT OF THE LABELING OF THEDUG:Cerezyme(Imiglucerase for in jection)[J/OL]. FDA,2003(2016-01-06). http://www. fda. gov/cder/foi/label/2005/20367 s0661b1. pdf.
[5]
China Food and Drug Administration. Data Search. Imiglucerase[EB/OL]. [2016-01-15]. http://app1. sfda. gov. cn/datasearch/face3/base. jsp.
[6]
GU J L, LU Y Q, ZHONG C, et al. Comparative analysis to rare disease pharmaceutical policydevelopment status in foreign countries[J]. Soft Sci Health(�������ѧ), 27(7): 393-396.
[7]
LUO X P, WANG T Y. Look from gaucher disease diagnosis and treatment status quo of our country road to the future of rare diseases[J]. Chin J Ped(�л�������־), 2015, 53(4):254-255.
[8]
XIN X X, GUAN X D, SHI L W. Research on rare disease security mechanism in China based on the affordability evaluation of 5 rare diseases[J]. J China Pharm(�й�ҩ��),2014, 25(5):404-407.
[9]
HE J J, ZHANG Y B, XIA S J, et al. Social security system of rare diseases in European Union and its implications for China[J]. Chin J Health Policy(�й����������о�) , 2011, 5(7): 52-59.
2016, Vol. 51 
